Femasys makes women's health devices and diagnostics for fertility and permanent birth control, sold mainly to gynecologists and clinics. It last closed at $1.14 on Nov 17, down 10.94% on the day.
FEMY · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 23% below its 20 day and 66% below its 50 day average. It is 381% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the 52 week low at $1.07, and the nearest resistance the Pivot at $1.17.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 14.0%/day
Key levels
$20.8052 week high+1724.6%
$5.49200 day average+381.6%
$2.53100 day average+121.9%
$1.8950 day average+65.8%
$1.55Swing high (Nov 12)+36.0%
$1.4020 day average+22.8%
$1.26Pivot R1+10.5%
$1.17Pivot+2.6%
$1.14Last close
$1.0752 week low−6.1%
$1.04Pivot S1−8.8%
Indicators
RSI (14)
31.12
Weak, oversold below 30
Neutral
MACD
-0.16
Above its signal line
Bullish
Stochastic
28.0
Middle of its range
Neutral
ADX (14)
52.7
Strong downtrend
Williams %R
-85.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-227.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−16.8%
Change over 10 sessions
Bearish
ATR (14)
$0.16
Typical daily range, 14.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 75.4%/day
Key levels
$20.8052 week high+1724.6%
$5.49200 day average+381.6%
$2.53100 day average+121.9%
$1.8950 day average+65.8%
$1.55Swing high (Nov 12)+36.0%
$1.4020 day average+22.8%
$1.26Pivot R1+10.5%
$1.17Pivot+2.6%
$1.14Last close
$1.0752 week low−6.1%
$1.04Pivot S1−8.8%
Indicators
RSI (14)
27.64
Oversold below 30
Oversold
MACD
-1.53
Above its signal line
Bullish
Stochastic
4.9
Near the bottom of its range
Oversold
ADX (14)
27.3
Trending down
Williams %R
-97.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-122.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−59.0%
Change over 10 sessions
Bearish
ATR (14)
$0.86
Typical daily range, 75.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for FEMY
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how FEMY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow FEMY usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How FEMY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FEMY is in one of them and how their past FEMY trades turned out.
Femasys is a women's health company based in Suwanee, Georgia, that makes medical devices and diagnostic products. Its fertility products include FemaSeed, a treatment that places sperm directly into the fallopian tube, along with FemSperm sperm preparation kits and FemVue, an ultrasound test of the fallopian tubes. It also offers FemBloc, a permanent birth control option that does not require surgery, along with the FemChec and FemCath products. Its customers are gynecologists, fertility clinics and other healthcare practitioners who treat women and couples.